Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 17, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a connected device, like a special scale, can help monitor patients with severe obesity who are being treated with Wegovy®, a weight-loss medication. The goal is to collect real-world data on important health measures, such as body weight, body composition (the amount of fat and muscle in the body), and cardiovascular health (how well the heart and blood vessels are working).
To be eligible for this study, participants must be adults over 18 years old who have reached the highest dose of Wegovy® and are able to provide written consent. Unfortunately, individuals who are pregnant or breastfeeding, those who do not speak French, or those under legal protection will not be able to participate. While the trial is not yet recruiting participants, those who join can expect to use the connected scale regularly, helping researchers gather valuable information to improve obesity treatment in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Man or woman aged over 18 years
- • Patients who have reached the maximum dose of their treatment with Wegovy®
- • Written consent
- Exclusion Criteria:
- • Patient on AME (state medical aid)
- • Pregnant or breastfeeding woman
- • Patient who does not speak French
- • Adults under legal protection
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Sébastien Czernichow, MD, PhD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported